Investor News

Acorda Therapeutics Hires Jane Wasman as Executive Vice President, General Counsel and Corporate Secretary

07/06/2004

Hawthorne, NY July 6, 2004 - Acorda Therapeutics announced today that Jane Wasman, J.D., has joined the Company as Executive Vice President, General Counsel and Corporate Secretary. This is a new position reporting to the President/CEO. In her role, Ms. Wasman will be responsible for overseeing all legal and intellectual property matters pertaining to the Company.

Ms. Wasman most recently was Staff Vice President and Associate General Counsel at Schering-Plough Corporation, supporting U.S. pharmaceuticals operations, including sales and marketing programs and related commercial and compliance activities, FDA regulatory matters, and research and development activities. Among previous roles at Schering-Plough, she headed the International Legal Group. Prior to joining Schering-Plough, Ms. Wasman was a litigation attorney at Fried, Frank, Harris, Shriver & Jacobson where she was involved in all aspects of commercial litigation, including securities, business fraud, environmental, product liability and commercial disputes. Ms. Wasman earned her J.D. from Harvard Law School and her undergraduate degree from Princeton University, Magna Cum Laude.

Ron Cohen, M.D., President and CEO of Acorda Therapeutics commented, “Jane Wasman has an outstanding record of accomplishment and deep experience across all aspects of commercial pharmaceutical operations. We are delighted to welcome her as a key addition to Acorda's management team.”

Acorda Therapeutics, a privately-held biotechnology company, is developing therapies for spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. The Company's lead product, Fampridine-SR, is being developed in human clinical trials for both MS and SCI. The Company's clinical-stage pipeline also includes valrocemide, which it is developing with Teva Pharmaceutical Industries Ltd. for the treatment of epilepsy and bipolar disorder. Additionally, Acorda is developing multiple approaches to the regeneration and repair of the spinal cord and brain.

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At COMPANY NAME, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to COMPANY NAME to send you the requested Investor Email Alert updates.

* Required